摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,2-difluoro-2-(3-methoxyphenyl)ethanol | 915133-58-3

中文名称
——
中文别名
——
英文名称
2,2-difluoro-2-(3-methoxyphenyl)ethanol
英文别名
2,2-Difluoro-2-(3-methoxyphenyl)ethan-1-ol
2,2-difluoro-2-(3-methoxyphenyl)ethanol化学式
CAS
915133-58-3
化学式
C9H10F2O2
mdl
——
分子量
188.174
InChiKey
AKLWBZHODREDAV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    282.9±40.0 °C(Predicted)
  • 密度:
    1.210±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    13
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1,6-二溴己烷2,2-difluoro-2-(3-methoxyphenyl)ethanol 在 sodium hydride 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 2.0h, 以57%的产率得到1-{2-[(6-bromohexyl)oxy]-1,1-difluoroethyl}-3-methoxybenzene
    参考文献:
    名称:
    WO2006/122788
    摘要:
    公开号:
  • 作为产物:
    描述:
    2,2-二氟-2-(3-甲氧基苯基)乙酸乙酯β-difluoro-γ-methylbenzene propanol 以The title compound was obtained (3.19 g, 90%) as oil的产率得到2,2-difluoro-2-(3-methoxyphenyl)ethanol
    参考文献:
    名称:
    Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 AdrenergicReceptor
    摘要:
    本公开涉及式(I)的4-(2-氨基-1-羟乙基)苯酚衍生物,以及包含它们的制药组合物,以及它们作为BETA2肾上腺素能受体激动剂在治疗中的使用。
    公开号:
    US20120115826A2
点击查看最新优质反应信息

文献信息

  • Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor
    申请人:Duran Carlos Puig
    公开号:US20090042933A1
    公开(公告)日:2009-02-12
    A compound of formula (I) or a pharmaceutically-acceptable salt, solvate or stereoisomer thereof wherein R 1 is a group chosen from —CH 2 OH and —NHC(O)H; R 2 is a hydrogen atom or R 1 together with R 2 form the group —NH—C(O)—CH═CH—, wherein the nitrogen atom is bound to the carbon atom in the phenyl ring holding R 1 and the carbon atom is bound to the carbon atom in the phenyl ring holding R 2 ; R 3 is chosen from a hydrogen atom, a halogen atom and groups chosen from —SO—R 5 , —SO 2 —R 5 , —NH—CO—NH 2 , —CO—NH 2 , hydantoino, C 1-4 alkyl, C 1-4 alkoxy and —SO 2 NR 5 R 6 ; R 4 is chosen from a hydrogen atom, a halogen atom and a C 1-4 alkyl group; R 5 is chosen from a C 1-4 alkyl group and a C 3-8 cycloalkyl group; R 6 is independently chosen from a hydrogen atom and a C 1-4 alkyl group; n, p and q are independently 0, 1, 2, 3 or 4; m and s are independently 0, 1, 2 or 3; and r is 0, 1 or 2 with the provisos that at least one of m and r is not 0, the sum n+m+p+q+r+s is 7, 8, 9, 10, 11, 12 or 13, and the sum q+r+s is 2, 3, 4, 5 or 6.
    化合物的化学式(I)或其药学上可接受的盐、溶剂化合物或立体异构体,其中R1是从—CH2OH和—NHC(O)H中选择的基团;R2是氢原子或R1与R2一起形成—NH—C(O)—CH═CH—的基团,其中氮原子与持有R1的苯环中的碳原子结合,碳原子与持有R2的苯环中的碳原子结合;R3从氢原子、卤原子和从—SO—R5、—SO2—R5、—NH—CO—NH2、—CO—NH2、hydantoino、C1-4烷基、C1-4烷氧基和—SO2NR5R6中选择的基团;R4从氢原子、卤原子和C1-4烷基中选择;R5从C1-4烷基和C3-8环烷基中选择;R6独立选择从氢原子和C1-4烷基中选择;n、p和q独立选择0、1、2、3或4;m和s独立选择0、1、2或3;r为0、1或2,但至少有一个m和r不为0,n+m+p+q+r+s之和为7、8、9、10、11、12或13,且q+r+s之和为2、3、4、5或6。
  • Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 Adrenergic Receptor
    申请人:PUIG DURAN Carlos
    公开号:US20120101075A2
    公开(公告)日:2012-04-26
    The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the BETA2 adrenergic receptor.
    本公开涉及式(I)的4-(2-氨基-1-羟乙基)苯酚衍生物,以及包含它们的药物组合物,以及它们作为BETA2肾上腺素能受体激动剂在治疗中的使用。
  • DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR
    申请人:PUIG DURAN Carlos
    公开号:US20110251165A1
    公开(公告)日:2011-10-13
    The present invention provides a compound of formula (I) wherein: R 1 is a group selected from —CH 2 OH, —NHC(O)H and R 2 is a hydrogen atom; or R 1 together with R 2 form the group —NH—C(O)—CH═CH— wherein the nitrogen atom is bound to the carbon atom in the phenyl ring holding R 1 and the carbon atom is bound to the carbon atom in the phenyl ring holding R 2 ; R 3 is selected from hydrogen and halogen atoms or groups selected from —SO—R 5 , —SO 2 —R 5 , —NH—CO—NH 2 , —CO—NH 2 , hydantoino, C 1-4 alkyl, C 1-4 alkoxy and —SO 2 NR 5 R 6 ; R 4 is selected from hydrogen atoms, halogen atoms and C 1-4 alkyl groups; R 5 is a C 1-4 alkyl group or C 3-8 cycloalkyl; R 6 is independently selected from hydrogen atoms and C 1-4 alkyl groups; n, p and q are independently 0, 1, 2, 3 or 4; m and s are independently 0, 1, 2 or 3; r is 0, 1 or 2; with the provisos that at least one of m and r is not 0; the sum n+n+p+q+r+s is 7, 8, 9, 10, 11, 12 or 13; the sum q+r+s is 2, 3, 4, 5 or 6 or a pharmaceutically-acceptable salt, solvate or stereoisomer thereof.
    本发明提供了化合物(I)的公式,其中:R1是从—CH2OH,—NHC(O)H和R2是氢原子中选择的一个基团;或者R1与R2一起形成—NH—C(O)—CH═CH—基团,其中氮原子与持有R1的苯环中的碳原子结合,碳原子与持有R2的苯环中的碳原子结合; R3从氢原子和卤原子或从—SO—R5,—SO2—R5,—NH—CO—NH2,—CO—NH2,海因酸,C1-4烷基,C1-4烷氧基和—SO2NR5R6中选择的基团中选择; R4从氢原子,卤原子和C1-4烷基基团中选择; R5是C1-4烷基或C3-8环烷基; R6是独立选择的氢原子和C1-4烷基基团; n,p和q独立选择为0,1,2,3或4; m和s独立选择为0,1,2或3; r为0,1或2; 其中至少一个m和r不为0; n + n + p + q + r + s之和为7,8,9,10,11,12或13; q + r + s之和为2,3,4,5或6或其药学上可接受的盐,溶剂或立体异构体。
  • Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 AdrenergicReceptor
    申请人:PUIG DURAN Carlos
    公开号:US20120115826A2
    公开(公告)日:2012-05-10
    The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the BETA2 adrenergic receptor.
    本公开涉及式(I)的4-(2-氨基-1-羟乙基)苯酚衍生物,以及包含它们的制药组合物,以及它们作为BETA2肾上腺素能受体激动剂在治疗中的使用。
  • Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor
    申请人:Almirall, S.A.
    公开号:US08242177B2
    公开(公告)日:2012-08-14
    The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the BETA2 adrenergic receptor.
    本公开涉及公式(I)的4-(2-氨基-1-羟乙基)苯酚衍生物,以及包含它们的制药组合物,以及它们作为BETA2肾上腺素能受体激动剂在治疗中的应用。
查看更多